Early Access — free while we kick the tires
EdgarHawk

Ashiya Mona

Director

Director
4 filings analyzed · 2 companies · Latest 2025-09-02

Companies

Company Buys Sells Direction
Shattuck Labs, Inc. STTK 2 0 Net buying
Disc Medicine, Inc. IRON 3 24 Net selling

Activity

September 2025
2025-09-02 Shattuck Labs, Inc. STTK
medium
Buy
6,306,127 shares
$5,471,826
Significance 4/10

Director Ashiya Mona buys 6,306,127 shares at $0.87 on 2025-08-25, investing $5,471,826.40 amid stock down 73.9% from 52-week high

Director Ashiya Mona purchased 6.31M shares across 2 separate transactions on 2025-08-25 at a blended average price of $0.87, committing approximately $5.5M. The purchase occurred when STTK was trading 73.9% below its 52-week high of $3.87, though the stock is up 38.0% over the prior 30 days. Notably, Mona's cross-ticker track record shows 20 prior sells with a 90-day well-timed rate of 100.00%, indicating her historical sell decisions have been followed by stock declines—a pattern that does not extend to buy decisions in the available metrics. The company reported zero revenue in the latest quarter and a net loss of $12.5M while unprofitable over its most recent full fiscal year, creating substantial execution risk alongside the deeply depressed valuation.

March 2025
2025-03-21 Disc Medicine, Inc. IRON
high
Sell
52,429 shares
$2,831,987
Significance 7/10

Director Ashiya Mona sold 52,429 shares across 9 transactions (March 19-21, 2025) at blended avg $54.02, reducing stake 21.9% to 187,297 shares.

Director Ashiya Mona executed 9 separate sales totaling 52,429 shares for $2,831,986.74 between March 19–21, 2025, at prices ranging from $54.00 to $54.02. This represents a significant reduction in her holdings—from 239,726 shares to 187,297 shares, a 21.9% decrease. The stock is currently trading at $52.24, down 4.1% over 30 days and 19.0% over 90 days, and sits 22.8% below its 52-week high of $67.64. Across her cross-ticker history, Mona's prior sells show a 0.00% well-timed rate (none preceded subsequent declines), and her recent same-ticker history includes five other sales on March 12, 2025, with outcomes not yet measurable. The company reported a full-year net loss of $26,599,000, indicating ongoing unprofitability, which frames the liquidation context but does not alone explain directional intent from a single transaction.

2025-03-12 Disc Medicine, Inc. IRON
high
Sell
312,384 shares
$16,965,596
Significance 6/10

Director Ashiya Mona sold 312,384 shares (61.7% of holdings) for $17.0M over three days at blended avg $54.31

Ashiya Mona, a Director at Disc Medicine, executed 15 separate sales totaling 312,384 shares for $16,965,596.07 between March 10–12, 2025, reducing her position from 506,593 shares to 194,209 shares. The multi-day execution at prices ranging from $54.01 to $55.05 (blended average $54.31) represents a substantial reduction in holdings. Her prior sales at IRON (December 2023) subsequently saw positive 90-day returns of +13.4%, indicating her past IRON sell timing has not preceded declines at that ticker. The company reported a negative net income of $-26,599,000 over its most recent full fiscal year and is unprofitable, providing material context for insider disposition decisions. The current stock price of $53.93 is -20.3% from its 52-week high, and the 90-day change is -16.1%, suggesting the stock has retreated since earlier peaks.

June 2024
2024-06-20 Disc Medicine, Inc. IRON
high
Buy
83,334 shares
$3,000,024
Significance 6/10

Director Ashiya Mona purchases 83,334 shares ($3.0M) at $36.00; holds 235,391 shares post-transaction amid cluster buy and unprofitable fundamentals.

Ashiya Mona, a Director, executed 3 separate purchases totaling 83,334 shares for $3,000,024.00 on 2024-06-17, raising her stake from 152,057 to 235,391 shares (+54.8%). The transactions occurred at $36.00 per share, notably below the current price of $41.25 and well below the 52-week high of $75.32 (current price is -45.2% from peak). A cluster buy pattern is present—2 other insiders also purchased within the prior 14 days. However, context tempers the signal: the company reported net income of $-26,949,000.00, indicating unprofitability, and the insider's prior transaction record at IRON shows 5 historical sales (all on 2023-12-14) that were poorly timed, with 90-day returns averaging +10.9% after each sale—meaning the insider sold before subsequent stock gains at this ticker. The 30-day post-purchase price movement (+32.0%) shows near-term strength, but the longer 90-day context (-31.9%) reflects volatility in an unprofitable name. The significance lies in the substantial equity commitment and coordinated insider activity, offset by unfavorable historical timing at this specific ticker and negative net income.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access